Royalty Pharma (RPRX) EBIT (2019 - 2026)
Royalty Pharma (RPRX) posted EBIT of $563.0 million for Q1 2026, up 44.97% sequentially from $388.4 million in Q4 2025, and up 5.4% YoY from $534.2 million in Q1 2025.
Royalty Pharma (RPRX) EBIT (2019 - 2026) Analysis & Trends
Royalty Pharma has reported EBIT for 8 years, with the latest figure at $563.0 million in Q1 2026.
- Quarterly EBIT rose 5.4% year-over-year to $563.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 16.42% YoY) and the FY2025 annual result came in at $1.6 billion, up 20.66% from the prior year.
- EBIT advanced to $563.0 million in Q1 2026 per RPRX's latest filing, from $388.4 million in the prior quarter.
- Over five years, EBIT peaked at $735.1 million in Q3 2024 and troughed at -$482.7 million in Q4 2022.
- A 5-year average of $306.7 million and a median of $361.5 million in 2024 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2025: EBIT plunged 414.6% in 2022, then surged 824.08% in 2025.
- Over 5 years, EBIT stood at -$482.7 million in 2022, then surged by 226.98% to $612.9 million in 2023, then sank by 41.02% to $361.5 million in 2024, then rose by 7.43% to $388.4 million in 2025, then surged by 44.97% to $563.0 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered $563.0 million, $388.4 million, and $427.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -365.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 133.12 Mn |
| Mar 31, 2026 | 563.04 Mn |
| Dec 31, 2025 | 388.38 Mn |
| Sep 30, 2025 | 427.16 Mn |
| Jun 30, 2025 | 209.80 Mn |
| Mar 31, 2025 | 534.18 Mn |
| Dec 31, 2024 | 361.51 Mn |
| Sep 30, 2024 | 735.07 Mn |
| Jun 30, 2024 | 269.63 Mn |
| Mar 31, 2024 | -73.77 Mn |
| Dec 31, 2023 | 612.90 Mn |
| Sep 30, 2023 | 151.44 Mn |
| Jun 30, 2023 | 248.84 Mn |
| Mar 31, 2023 | 478.97 Mn |
| Dec 31, 2022 | -482.66 Mn |
| Sep 30, 2022 | 192.21 Mn |
| Jun 30, 2022 | 377.79 Mn |
| Mar 31, 2022 | 219.72 Mn |
| Dec 31, 2021 | 153.42 Mn |
| Sep 30, 2021 | 303.05 Mn |